New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer annual meeting, including: Antengene, Carisma, Celularity, CG Oncology.
Researchers working at Lerner Research Institute, Cleveland Clinic reported in the November 8, 2021, issue of NatureCancer that an inhibitor of the beta-amyloid producing enzyme, BACE1, could reprogram tumor-promoting M2 macrophages to exert M1 tumor-suppressing activities in animal models of glioblastoma multiforme.
Oncorus Inc. offered initial safety, tolerability and immune activation and clinical response data from its ongoing phase I trial with ONCR-177 at the Society for Immunotherapy of Cancer (SITC) meeting. In the fully enrolled and completed surface lesion, dose-escalation part of the study, single-agent ONCR-177, an oncolytic herpes simplex virus for intratumoral injection, proved well-tolerated with no dose-limiting toxicities.
It’s been a decade since the first checkpoint inhibitors were approved, but the problem of low response rates remains in many forms of cancer. Highlight Therapeutics SL, of Valencia, Spain, hopes to change all that with an approach that primes the body to become more responsive to immunotherapies.
New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer annual meeting, including:: A2, Achilles, Actinium, Actym, Adaptimmune, Adicet, Affimed, Agenus, Anaveon, Apexigen, Aravive, Asher, Aulos, Bicara, Bolt, Candel, Celldex, Cellectis, Celyad, Cero, Checkmate, Codiak, Compugen, Cue, Editas, Elicio, F-star, G1, Grey Wolf.
RSS
